Pharmacogenetics of Warfarin Induction and Inhibition
This research study will help determine how a person's genetic makeup affects their response to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. The investigators are investigating the drug interactions with the commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart attacks, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic profiles react differently to warfarin when it is combined with other drugs. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population. Genetic profiles of subjects are determined from their participation in the Pharmacogenetics Registry study (investigator Richard Brundage, University of Minnesota).
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The research question is: How does CYP2C9 genotype modify warfarin drug interactions?
People differ in their genetic makeup. This includes differences in genes involved in drug metabolism, transport, and effect in the body. People with certain genetic profiles produce altered enzymes, transporters, and receptors that may respond in different ways to drugs. Altered enzymes cause some drugs to be broken down at a different rate than normal. As a result, drug concentrations build up in the blood, and increase the risk of side effects. Furthermore, when two drugs are taken together, the possibility exists for the drugs to interact, with one drug causing a change in the metabolism of the other or both of the drugs. It is not known whether people with an altered genetic makeup also have an altered experience with drug interactions. Altered drug transporters can affect the absorption and elimination of drugs as compared to normal causing differences in how long the drug stays in the body. Finally, altered drug receptors can respond differently to drugs and, thus, produce altered desired or undesired effects.
In this study, the investigators will be investigating the drug interactions with the commonly used anticoagulant drug warfarin in subjects with five different CYP2C9 genotypes. The CYP2C9 genotype is particularly important because this drug metabolizing enzyme governs the metabolic clearance of the more potent chemical entity (the S-enantiomer) of the drug. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, myocardial infarction, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic alleles of the CYP2C9 genotype react differently to warfarin when it is combined with an antifungal (fluconazole) that inhibits CYP2C9-mediated metabolism and an antibiotic (rifampin) that induces CYP2C9-mediated metabolism. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population.
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55414
- Clinical and Translational Science Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subjects will be 18-60 years old.
- Women of child bearing age must be willing to use measures to avoid conception during the study period.
- Subjects must agree not to take any known substrates, inhibitors, inducers or activators of either CYP2C9 or CYP3A4 from 1 week prior to the start of each study through the last day of study.
Exclusion Criteria:
- Current cigarette smoker
- Abnormal renal, liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.
- Allergy to warfarin, fluconazole or rifampin and other chemically related drugs.
- Recent ingestion (< 1 week) of any medication known to be metabolized by or alter CYP2C9 or CYP3A4 activity.
- A positive pregnancy test at the time of the pharmacokinetic study.
- Lab tests indicative of abnormal blood clotting capacity.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: CYP2C9*1/*1 Genotype
This genotype is considered the wild type genotype.
Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
|
|
Otro: CYP2C9*1B/*1B Haplotype
Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
|
|
Otro: CYP2C9*1/*3 Genotype
Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
|
|
Otro: CYP2C9*2/*3 Genotype
Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
|
|
Otro: CYP2C9*3/*3 Genotype
Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Warfarin Clearance.
Periodo de tiempo: Over three (two for CYP2C9*1B/*1B participants) 12-16 day study periods.
|
Warfarin enantiomer (S-warfarin and R-warfarin) clearance was measured in healthy volunteers genotyped for CYP2C9*1/*1, CYP2C9*1B/*1B, CYP2C9*1/*3, CYP2C9*2/*3 and CYP2C9*3/*3 to determine the magnitude of the warfarin-fluconazole (inhibition) and warfarin-rifampin (induction) drug interactions.
|
Over three (two for CYP2C9*1B/*1B participants) 12-16 day study periods.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Richard Brundage, PhD, University of Minnesota
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Agentes antibacterianos
- Inhibidores de enzimas del citocromo P-450
- Agentes leprostáticos
- Antagonistas de hormonas
- Inductores de enzimas de citocromo P-450
- Agentes antifúngicos
- Anticoagulantes
- Inhibidores de la síntesis de esteroides
- Inductores de citocromo P-450 CYP3A
- Agentes antituberculosos
- Inhibidores de la 14-alfa desmetilasa
- Antibióticos, Antituberculosos
- Inductores de citocromo P-450 CYP2B6
- Inductores de citocromo P-450 CYP2C8
- Inductores del citocromo P-450 CYP2C19
- Inductores de citocromo P-450 CYP2C9
- Inhibidores del citocromo P-450 CYP2C9
- Inhibidores del citocromo P-450 CYP2C19
- Rifampicina
- Warfarina
- Fluconazol
Otros números de identificación del estudio
- 0807M38361
- P01GM032165-26 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .